Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Dubel

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Annals of Surgical Oncology|September 24, 2010
Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survivalSuzanne C Schiffman, Tiffany Metzger, Gregory Dubel, et al.
American Journal of Clinical Oncology|May 8, 2013
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II studyHoward Safran, Kevin P Charpentier, Andreas Kaubisch, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Annals of Surgical Oncology|September 24, 2010
Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survivalSuzanne C Schiffman, Tiffany Metzger, Gregory Dubel, et al.
American Journal of Clinical Oncology|May 8, 2013
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II studyHoward Safran, Kevin P Charpentier, Andreas Kaubisch, et al.
Pageof 1